This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as a Hybrid Event from September 20-30, 2021
Live Digital Agenda Runs 11am-3pm EST from Sept 28-30Boston Convention and Exhibition Center

Andrew Tustian
Director at Regeneron Pharmaceuticals

Profile

Andrew leads the viral vector process development group at Regeneron Pharmaceuticals, focused on developing bioprocesses for Adeno-associated virus (AAV) based viral vectors. Andrew has worked at Regeneron since 2009. Prior to moving to gene therapy Andrew co-led the purification development group for protein therapeutics, working on Fc-fusion, monoclonal antibody, and bispecific processes. He has worked on the process development for the FDA-approved drugs Dupixent®, Libtayo®, Inmazeb™, Kevzara®, Evkeeza™ and Praluent®, and helped develop the bispecific antibody platform at Regeneron. Andrew received his doctorate in biochemical engineering from University College London and his undergraduate masters in biochemistry from the University of Oxford.

Agenda Sessions

  • ROOM 258AB: Panel Discussion – Strategies to Accelerate and Optimize Process Development, Production and Time to Clinic for Novel Modalities

    2:00pm
  • Panel Discussion: Overcoming Downstream Challenges for Emerging Modalities

    11:40am